Description: Jaguar Animal Health, Inc., a development-stage animal health company, focuses on developing and commercializing gastrointestinal products for companion and production animals. The company's lead prescription drug product candidate includes Canalevia, a canine-specific formulation of Crofelemer for the treatment of CID and general acute watery diarrhea in dogs. It is also developing Crofelemer to treat acute colitis in horses and general acute watery diarrhea in cats; Neonorm, an enteric-coated tablet for scours in preweaned dairy calves, as well as other animal species, such as horses, goats, and sheep; and other product candidates, including Virend and NP-500. The company was founded in 2013 and is headquartered in San Francisco, California. Jaguar Animal Health, Inc. is a subsidiary of Napo Pharmaceuticals, Inc.
Home Page: jaguar.health
JAGX Technical Analysis
200 Pine Street
San Francisco,
CA
94104
United States
Phone:
415 371 8300
Officers
| Name | Title |
|---|---|
| Ms. Lisa A. Conte | Founder, CEO, Pres & Director |
| Mr. Jonathan S. Wolin CPA, J.D., M.B.A. | Chief of Staff, Chief Compliance Officer & Gen. Counsel |
| Mr. Ian H. Wendt M.B.A. | Chief Commercial Officer |
| Dr. Steven R. King Ph.D. | Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec. |
| Ms. Carol R. Lizak | Chief Financial Officer |
| Dr. Pravin R. Chaturvedi Ph.D. | Chief Scientific Officer & Chair of Scientific Advisory Board |
| Mr. Peter Hodge | Sr. Director of Investor Relations, Bus. Devel. & Special Events |
| Dr. Karen J. Brunke Ph.D. | Exec. VP of Corp. & Bus. Devel. |
| Mr. David Sesin | Chief Manufacturing Officer |
| Dr. Michael K. Guy D.V.M., M.S., Ph.D. | VP of Preclinical & Nonclinical Studies |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.6525 |
| Price-to-Sales TTM: | 1.5423 |
| IPO Date: | 2015-05-13 |
| Fiscal Year End: | December |
| Full Time Employees: | 52 |